Hello, and welcome to the 2024 Annual Meeting of Stockholders of Schrödinger, Inc. You can submit questions at any time by clicking the Q&A button in the virtual meeting website. It is now my pleasure to turn today's meeting over to Ramy Farid, Chief Executive Officer of Schrödinger, Inc. Good morning, and welcome to the 2024 Annual Meeting of Stockholders of Schrödinger. I'm Ramy Farid, Chief Executive Officer, and I will be presiding over this meeting. At this time, I call the meeting to order and turn it over to Yvonne Tran, our Chief Legal Officer and Corporate Secretary. Thanks, Ramy. Good morning, everyone. Before we begin the formal business of the meeting, I'd like to make some introductions. Joining us today, in addition to Ramy, are the following members of our Board of Directors: Michael Lynton, our Chair, Gary Ginsberg, Jeffrey Chodakewitz, Nancy Thornberry, Richard Friesner, Rosana Kapeller-Libermann, Gary Sender, and Arun Oberoi. In addition, the following members of our management team are present today: Ramy Farid, Chief Executive Officer, Geoff Porges, Chief Financial Officer, Jaren Madden, Senior Vice President, Investor Relations and Corporate Affairs, and myself, Yvonne Tran, Chief Legal Officer, Chief People Officer, and Corporate Secretary. I'd also like to introduce Dennis White and Allie Kreft, representatives from KPMG LLP, our independent registered public accounting firm; Tracy Oates, a representative from Broadridge Financial Solutions, who's been appointed to act as Inspector of Election; and Scott Lunin of WilmerHale, the company's legal counsel. Before we continue, we ask that you follow the rules of conduct and procedures for today's meeting, which have been posted to the following website: virtualshareholdermeeting.com/sdgr2024. Please note that various remarks that we may make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent quarterly report on Form 10-Q, which is on file with the SEC. In addition, these forward-looking statements represent the company's expectations only as of today. While we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so. Any forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to today. Please also note, I've received an affidavit from Schrödinger's representative at Broadridge Financial Solutions, certifying that the notice of the annual meeting was sent to all stockholders of record as of April 22, 2024, a copy of which will be included in the minutes of the meeting. Our first order of business today is to determine whether the shares represented at this meeting, either by means of remote communication or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Holders of 63,515,197 shares of common stock and 9,164,193 shares of limited common stock are entitled to vote at this meeting. The Inspector of Election has informed me that there are present, either by means of remote communication or by proxy, a total of 50,712,866 shares of common stock and 9,164,193 shares of limited common stock. This constitutes a majority in voting power of the shares issued and outstanding and entitled to vote at this meeting. Further, in the case of the election of the three Class I directors, this constitutes a majority in voting power of the shares of common stock issued and outstanding and entitled to vote on such matter. Based on the foregoing, I confirm that a quorum exists. We now turn to the items to be voted on today, as indicated in the notice of meeting and accompanying documents that we made available to our stockholders. The first item to be voted on is the election of three Class I directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The three nominees for election are Ramy Farid, Gary Ginsberg, and Arun Oberoi. The second item to be voted on is the approval of an advisory vote on executive compensation. The proxy statement for this meeting contained the text of the resolution that stockholders are being asked to approve. The third item to be voted on is the approval of an amendment to the Schrödinger, Inc 2022 Equity Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 5 million shares. The fourth item to be voted on is the approval of an amendment to the Schrödinger, Inc. 2020 Employee Stock Purchase Plan to increase the number of shares of common stock available for issuance thereunder by 413,155 shares. The fifth item to be voted on is the approval of an amendment to the Schrödinger, Inc Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. Finally, the last item to be voted on is the ratification of the selection of KPMG LLP as Schrödinger's independent registered public accounting firm for the current fiscal year. If you have any questions on the proposals, please submit them on the virtual meeting website. If you submit a question, please also include your name and affiliation to Schrödinger. We'll pause briefly now to allow stockholders to submit questions. I remind you that there will be an opportunity for general questions not related to the proposals after the formal portion of the meeting has concluded. Matt, do we have any questions pertaining to the proposals at this time? There are no questions at this time. Thanks, Matt. As there are no questions, we'll move on to voting on the proposals. The polls are now open for each of the matters I described earlier that are to be voted on today. If you previously voted by proxy, whether by mail, telephone, or internet, you should not vote now unless you wish to change your vote. Your submission of a vote now will revoke all proxies. For stockholders who provided a proxy, the persons named in the proxy will vote your shares as indicated on the proxy. For any stockholders who have not submitted a proxy and who wish to vote now, or for any stockholders who submitted a proxy but wish to revoke their proxy or change their vote, you may vote by using the Vote Here link provided on the virtual meeting website. Please follow the instructions there. We'll pause briefly now to allow stockholders to vote. We have now concluded the business items on the agenda for this meeting. The polls are now closed, and the Inspector of Election has tabulated the votes. We have the preliminary report of the results of today's meeting. Based on this report, I can announce that first, each of the nominees for director, Ramy Farid, Gary Ginsberg, and Arun Oberoi, has been elected as a Class I director. Second, the advisory resolution approving executive compensation has been approved. Third, the amendment to the Schrödinger Inc 2022 Equity Incentive Plan has been approved. Fourth, the amendment to the Schrödinger Inc 2020 Employee Stock Purchase Plan has been approved. Fifth, the amendment to the Schrödinger Inc Restated Certificate of Incorporation has been approved. And finally, the appointment of KPMG LLP has been ratified. The final vote results will be included in a Form 8-K that will be filed within 4 business days after this meeting. As there is no further business to conduct, the formal part of the meeting is adjourned. We will now hear a report from Ramy Farid, our CEO, and answer questions from stockholders. Ramy, I'm turning it over to you. Thanks, Yvonne. So I'll start with a quick overview of the company. We were founded over 30 years ago and have a long track record of significant innovations in the field of computational molecular design or digital chemistry. We have over 850 employees, with more than 40% having PhDs, and over 50% are in R&D. We have nearly 1,800 software customers, including all the top 20 pharma companies. We also have a pipeline of over 24 collaborative and proprietary drug discovery programs that I'll tell you a little bit about in a few moments. So drug discovery is incredibly challenging, and the failure rates are unacceptably high, in our view. Our vision for the future of drug discovery is to be able to explore a significant portion of available chemical space and to accurately compute all key molecular properties. That's our vision. This would allow us to identify the ideal molecules that possess all the desired properties and have the highest potential to become, for example, an effective and safe drug. In our effort to realize this vision, we've developed a computational platform, which is broadly used across the biopharma industry, that leverages both physics-based first principles methods, and state-of-the-art machine learning and AI. The physics-based methods, which are highly accurate, are used to generate massive training sets for machine learning, and this powerful combination of methods has allowed for the exploration of vast amounts of chemical space accurately enough to impact drug discovery programs in a really truly meaningful way. So we have a multipronged business that is enabled by the computational platform that we've developed over the last 30+ years. We license our software to life sciences and materials science companies and academic institutions worldwide. We also establish drug discovery and materials design collaborations, and we have a drug discovery and drug development pipeline of proprietary programs. Importantly, these businesses are highly synergistic. We incorporate learnings from interactions with our very large customer base into our platform, and we validate the platform through application of our technology in collaborative and proprietary programs. Our drug discovery collaborations have been quite successful. There are currently eight programs from these collaborations in the clinic, and a handful in IND-enabling studies with the potential to enter the clinic in the future. You can see that one of these clinical programs is in Phase III, two are in Phase II, and the rest are in Phase I. We also have a number of additional programs in discovery and preclinical development with a number of partners. We are also advancing a pipeline of internal preclinical and clinical programs. Our most advanced programs, SGR-1505 and SGR-2921, are in Phase I clinical studies, and our third program, SGR-3515, will enter Phase I in Q3 of this year. We also have a number of programs in discovery in areas of oncology, immunology, and neurology that we're very excited about, and we look forward to providing updates on these programs as they progress. So on the final slide, I'll highlight our strategic priorities and anticipated upcoming milestones. We're focused on maintaining momentum in our software business, continuing to expand the scope of capabilities of our computational platform across life sciences and material science applications, advancing our lead proprietary programs to clinical proof of concept, and progressing our second wave of proprietary programs towards IND. Anticipated milestones are, as I mentioned previously, initiating the Phase I clinical study for SGR-3515, and reporting initial clinical data from our Phase I studies for SGR-1505 and SGR-2921. Matt, are there any questions from stockholders? I'd like to remind our stockholders that we are answering questions that fall within the guidelines of our rules of conduct and procedures set forth for our annual meeting. If anyone has a question that is not answered during today's meeting, you may email your questions to investor relations at ir@schrodinger.com. Ramy, we have no questions at this time. Thanks, Matt. I'd like to thank our stockholders for attending our annual meeting and for your continued support of Schrödinger. We look forward to providing you with updates on our business throughout the year. Thank you all for your time today.